- Home
- LI vs BIIB Comparison
LI vs BIIB Comparison
Compare LI & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LI | BIIB |
|---|---|---|
| Founded | 2015 | 1978 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 29.9B |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | LI | BIIB |
|---|---|---|
| Price | $12.18 | $221.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 25 |
| Target Price | $19.66 | ★ $206.83 |
| AVG Volume (30 Days) | ★ 2.8M | 835.0K |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.15 |
| Revenue | N/A | ★ $9,890,600,000.00 |
| Revenue This Year | $18.98 | N/A |
| Revenue Next Year | $22.72 | N/A |
| P/E Ratio | ★ $29.50 | $102.82 |
| Revenue Growth | N/A | ★ 2.22 |
| 52 Week Low | $11.65 | $131.54 |
| 52 Week High | $26.94 | $222.85 |
Technical Indicators
Market Signals| Indicator | LI | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 62.25 |
| Support Level | $12.09 | $184.50 |
| Resistance Level | $12.39 | N/A |
| Average True Range (ATR) | 0.25 | 4.85 |
| MACD | -0.03 | 0.99 |
| Stochastic Oscillator | 7.94 | 91.12 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is one of China's leading new energy vehicle manufacturers. Founded in 2015, the company designs, develops, manufactures, and sells premium smart NEVs with a particular focus on family size premium SUVs and MPVs. Li Auto started volume production of its first model—the Li One, an SUV that is a premium plug-in electric vehicle- in November 2019. Besides PHEVs, its product portfolio now extends to EVs that are fully battery-powered, reaching a wide audience. It has sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger NEV market.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).